Cancers Treated:
Specializing In:
- Brain metastases in breast cancer
Research Interests:
- Novel therapies for breast cancer
- Biomarkers of treatment response and resistance
- Tumor–immune interactions and spatial biology
- Real-world treatment outcomes and disparities in care
Biography
I am a breast medical oncologist dedicated to providing personalized care and advancing treatments for breast cancer. I completed my hematology and oncology fellowship at Roswell Park. My research focuses on breast cancer biology, novel therapies, and biomarkers of treatment response and resistance. I also study real-world treatment outcomes and disparities in cancer care. My work has been recognized at leading oncology meetings, including ASCO, AACR, and SABCS, and has received multiple research awards. My goal is to translate scientific discoveries into more effective treatments while helping patients make informed decisions about their care.
Positions
Roswell Park Comprehensive Cancer Center
- Assistant Professor of Oncology
- Department of Medicine - Breast
State University of New York at Buffalo
- Assistant Professor of Oncology
Background
Education and Training
- 2011–2017 - MD - Rawalpindi Medical University, Rawalpindi, Pakistan
- 2014- Bachelor of Science- Punjab University, Lahore, Pakistan
Residency
- 2022 –2023 - Chief Resident, Internal Medicine, Louis A. Weiss Memorial Hospital / University of Illinois, Chicago, IL
- 2019–2022 - Internal Medicine Residency, Louis A. Weiss Memorial Hospital / University of Illinois, Chicago, IL
Fellowship
- 2023–2026 - Hematology/Oncology Fellowship, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Board Certification
- American Board of Internal Medicine
Professional Memberships
- American Society of Clinical Oncology (ASCO)
- American Society of Hematology (ASH)
- American Association for Cancer Research (AACR)
- Society for Immunotherapy of Cancer (SITC)
- American College of Physicians (ACP)
Honors & Awards
- 2026 - AACR oral presentation
- 2026 - ASCO Quality Care Symposium Featured Voice
- 2026 - Fellow Abstract Award, Empire State Hematology & Oncology Society
- 2026 - GRASP Advocate Choice Award
- 2026 - Gerald L. Logue Award for Outstanding Graduating Fellow, Roswell Park Comprehensive Cancer Center
- 2026 - NCCN Oncology Fellows Program
- 2025, 2026 - Conquer Cancer (ASCO) Merit Awards
- 2025 - American Society of Clinical Oncology (ASCO) Young Investigator Award
- 2025 - Charlie and Gloria Young Investigator Award
- 2025 - Margaret Foti Foundation Scholar-in-Training Award, San Antonio Breast Cancer Symposium
- 2025 - Society of Hematologic Oncology (SOHO) Young Investigator Award
- 2025 - Selected, SITC Women in Cancer Immunotherapy Network (WIN) Leadership Institute
- 2025 - ASCO oral presentation
- 2022- “Most Proficient Scholar Award,” Internal Medicine Residency
Publications
Shah Z, Lei L, Thakur R, Buradkar A, Alharbi M, Ombada M, Yao S, Chua A, Yu H, Badve S, Khoury T, Madabhushi A, Baid U, Kalinsky K, Kabraji S, Gandhi S. Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates. Journal of the National Cancer Institute. 2026;djag223.
Shah Z, Hundal J, Afridi SS, Aziz S, Djunadi TA, Deenadayalan V, Yao S, Kabraji SK, Iyengar NM, Gandhi S. GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis. Journal of Clinical Oncology. 2026;44(16_suppl):10548.
Shah Z, Kabraji S. Real-world brain metastasis outcomes with T-DXd versus tucatinib-based therapy in second-line HER2-positive metastatic breast cancer. Oncology AMJ. 2026;3(1):96–98.
Shah Z, Oturkar CC, Aijaz I, Yu H, Tarquini ML, Das GM, Kabraji S. A pilot, single-arm, phase II trial of tamoxifen plus pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer. Clinical Cancer Research. 2026;32(4_suppl):PS5-08-09.
Kawashima K, Oshi M, Yamada A, Narui K, Shah Z, Khoury T, Endo I, Takabe K. The clinical relevance of apocrine morphology in breast cancer depends on the estrogen receptor status. npj Breast Cancer. 2026;12:120.